Catalyst Pharmaceuticals Inc (STU:CN2)
€ 20.71 0.15 (0.73%) Market Cap: 2.46 Bil Enterprise Value: 2.04 Bil PE Ratio: 18.19 PB Ratio: 3.87 GF Score: 88/100

Catalyst Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 03:05PM GMT
Release Date Price: €11.26 (-1.19%)
Charles Duncan Cantor Fitzgerald;Analyst

I think we'll get started with the next presenting company from the Cantor Global Health Care Conference for 2023. I am Charles Duncan. I'm a senior biotechnology analyst for the firm, not referring to my age, but the number of companies I cover and how long I've covered them.

One of the companies that I've had the pleasure of covering for many years is Catalyst Pharmaceuticals, and I've seen it be transformed from a development-stage company to a commercial-stage company that seeks to really do well by doing right by patients to a company that has real business and has not only a growing revenue stream, which is profitable, but also has started to bring in other growth drivers, other pipeline candidates.

So it's a pleasure to introduce two people from the management of Catalyst Pharmaceuticals. Dr. Steven Miller, the company's Chief Operating Officer and Chief Scientific Officer. Steven, great to see you. Thank you for joining us. And Mr. Pat McEnany, the company's Co-Founder, President, and CEO. And it's just really great to have these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot